Home > Insider Trading > Filing (0001567619-20-021191)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1787306	Arcutis Biotherapeutics Inc.	ARQT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1252999	W David Osborne	C/O Arcutis Biotherapeutics, Inc. 2945 Townsgate Road, Suite 110 Westlake Village CA 91361	Chief Technical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-12-14	15,000	$30.00	250,533	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	62,478	Indirect	By Trust
Common Stock	62,478	Indirect	By Trust

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
Includes 1,254 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 1,038 shares on May 31, 2020 and 216 shares on November 30, 2020.
The securities are held of record by The Osborne Irrevocable Trust FBO John Osborne, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
The securities are held of record by The Osborne Irrevocable Trust FBO Sharon Osborne, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.